Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV000018591 | SCV001522813 | uncertain significance | Atypical hemolytic-uremic syndrome with C3 anomaly | 2019-12-16 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Labcorp Genetics |
RCV002513105 | SCV003443806 | uncertain significance | not provided | 2022-07-12 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies have shown that this missense change affects C3 function (PMID: 18796626, 25608561). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 17062). This variant is also known as D1093N. This missense change has been observed in individual(s) with clinical features of atypical hemolytic uremic syndrome (PMID: 18796626, 25608561, 33456446, 34169201; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 1115 of the C3 protein (p.Asp1115Asn). |
OMIM | RCV000018591 | SCV000038874 | risk factor | Atypical hemolytic-uremic syndrome with C3 anomaly | 2008-12-15 | no assertion criteria provided | literature only |